Alpine Immune Sciences to Present at Two Upcoming Healthcare Investor Conferences

Alpine Immune Sciences, Inc. ALPN, a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March.

Cowen 40^th Annual Healthcare Conference
Tuesday, March 3, 2020 at 11:20 a.m. Eastern Time in Boston, MA

Oppenheimer & Co. 30^th Annual Healthcare Conference
Tuesday, March 17, 2020, at 4:30 p.m. Eastern Time in New York, NY

A live webcast of each presentation will be available online by visiting the investor relations page of the Company's website, at https://ir.alpineimmunesciences.com/events. An archive of each webcast will be available on the Company's website for 30 days.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients' lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005841/en/